In heart failure with reduced ejection fraction (HFrEF) and an ejection fraction of 20%, should metoprolol succinate be used instead of metoprolol tartrate?

Metoprolol Succinate is Strongly Recommended Over Metoprolol Tartrate in HFrEF with EF 20%

In heart failure with reduced ejection fraction (HFrEF) and an ejection fraction of 20%, metoprolol succinate (extended-release) should be used instead of metoprolol tartrate, as only metoprolol succinate has proven mortality benefit in clinical trials and is specifically recommended in guidelines for HFrEF management. 1, 2, 3

Evidence-Based Beta-Blocker Selection

Only Three Beta-Blockers Have Proven Mortality Benefit

The ACC/AHA guidelines explicitly recommend only three beta-blockers for HFrEF: bisoprolol, carvedilol, and sustained-release metoprolol succinate 1, 2, 4, 3. These are the only agents proven in randomized controlled trials to reduce mortality and hospitalizations in patients with symptomatic HFrEF 2, 3.

• Metoprolol tartrate (immediate-release) is not included in guideline recommendations for HFrEF treatment 1, 2, 3
• The favorable findings with the three evidence-based beta-blockers should not be considered a class effect applicable to other beta-blockers 3

Why Metoprolol Succinate Over Tartrate

Pharmacokinetic and Pharmacodynamic Differences:

• Metoprolol succinate provides sustained beta-1 blockade over 24 hours with once-daily dosing, while metoprolol tartrate requires multiple daily doses to maintain therapeutic effect 5
• Metoprolol succinate produces lower peak plasma levels (one-fourth to one-half of tartrate peaks) but maintains more consistent beta-blockade throughout the dosing interval 5
• The extended-release formulation achieves 77% bioavailability with significantly lower peak-to-trough variation compared to immediate-release metoprolol 5

Clinical Trial Evidence:

• The MERIT-HF trial, which demonstrated mortality reduction in HFrEF, specifically used metoprolol succinate (CR/XL formulation) 1, 2
• Metoprolol succinate improved both systolic and diastolic left ventricular function, increased ejection fraction from 0.26 to 0.31, and demonstrated anti-remodeling effects 6
• Studies comparing formulations showed metoprolol succinate produced larger effects on heart rate suppression over 24 hours compared to immediate-release metoprolol 5

FDA-Approved Indication

Metoprolol succinate is FDA-approved specifically for "treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin" 5. The FDA label states it decreased mortality plus hospitalization rates in patients already receiving ACE inhibitors, diuretics, and digitalis 5.

Practical Implementation for EF 20%

Initiation Strategy

• Start metoprolol succinate at a low dose (12.5-25 mg once daily) in clinically stable patients 3, 7
• Ensure the patient is euvolemic and not requiring intravenous inotropes before initiation 3
• Beta-blockers can be safely initiated before hospital discharge if the patient is clinically stabilized 3

Target Dosing

• The target dose for metoprolol succinate is 200 mg once daily 4, 3
• Titrate upward every 2 weeks as tolerated, doubling the dose at each step 4, 3
• Achieving at least 50% of target dose (100 mg daily) is associated with improved outcomes 4

Common Pitfalls to Avoid

Do not substitute metoprolol tartrate for succinate: The formulations are not interchangeable for HFrEF management, as only succinate has mortality data 1, 2, 3. If a patient is on metoprolol tartrate, they should be converted to one of the three evidence-based beta-blockers 8.

Do not delay initiation: Beta-blockers should be started as soon as HFrEF is diagnosed, even if asymptomatic or if symptoms improve with other therapies 3. The mortality benefit persists regardless of symptom improvement 3.

Monitor for hypotension and bradycardia: With an EF of 20%, this patient has severely reduced cardiac function. Titrate cautiously, monitoring blood pressure and heart rate at each dose increase 3. However, mild bradycardia (heart rate 50-60 bpm) is acceptable if the patient is asymptomatic 3.

Avoid abrupt discontinuation: Sudden cessation of beta-blockers can precipitate acute decompensation 9, 10, 11. If discontinuation is necessary, taper gradually 9, 10, 11.

Combination with Other GDMT

This patient with EF 20% requires comprehensive guideline-directed medical therapy (GDMT):

• Metoprolol succinate should be combined with an ACE inhibitor (or ARB/ARNI), mineralocorticoid receptor antagonist, and SGLT2 inhibitor 2, 3
• All four medication classes should be initiated and titrated to target doses within 6-12 weeks of diagnosis 3, 12
• The sequence of initiation matters less than achieving target doses of all agents 3

Special Considerations

CYP2D6 polymorphisms: Metoprolol is metabolized almost exclusively by CYP2D6 13. Patients of European and Asian ancestry have higher rates of poor metabolizer phenotypes and may experience intolerance at guideline-directed doses 13. If metoprolol succinate cannot be titrated due to adverse effects, consider switching to carvedilol, which has less CYP2D6-dependent metabolism 13.

Comparative effectiveness: Meta-analyses show carvedilol and metoprolol succinate have similar effects on all-cause mortality in HFrEF 14. Either agent is appropriate, but metoprolol tartrate should not be used 14.